摘要:
The present invention provides small molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate ceil growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascujar disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to reduce circulating levels of ApoB- i 00 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.
摘要:
A compound of formula: wherein Ar 1 , Ar 2 , V, X, R 3 , R 4 , and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a "Cyclo(hetero)alkenyl Compound"); compositions comprising an effective amount of a Cyclo(hetero)alkenyl Compound; and methods for treating or preventing, e.g., pain, UI, an ulcer, IBD, or IBS in an animal, comprising administering to an animal in need thereof an effective amount of a Cyclo(hetero)alkenyl Compound are disclosed herein.
摘要:
Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.
摘要:
Disclosed herein are compositions and methods for treating colitis and other inflammatory bowel diseases, inter alia , indeterminate colitis, Crohn's disease, irritable bowel syndrome and ischemic colitis.
摘要:
The invention provides a water in oil or oil in water emulsion which comprises a (i) an oil phase, (ii) an aqueous phase and (iii) an ionic liquid surfactant wherein the ionic liquid surfactant is a salt of general formula (I): C + A - (I) the salt of general formula (I) existing in a liquid state at a temperature below 15O 0 C; at least one of the cation, C + , and anion, A - , comprising a hydrophobic tail group attached to an ionic head group; and A - represents an anion containing phosphorus, or an alkyl sulfate anion of general formula: ROSO 3 -
摘要:
Described are preferred processes for preparing alkenyl-substituted nitrogenous heterocycles such as vinylpyridines, which comprises reacting a corresponding methyl-substituted heterocycle with a C1 compound such as formaldehyde in the vapor phase over a zeolite catalyst having acidic and basic catalytic sites. The preferred zeolite is a medium-pore zeolite, for example having a constraint index of about 0.5 to about 12. Processes of the invention can be conducted as facile, one-step syntheses utilizing relatively low ratios of alkyl-substituted starting heterocycle (e.g. &agr;-picoline or &ggr;-picoline) to formaldehyde while nonetheless achieving high sensitivities and yields of the corresponding alkenyl compound.
摘要:
본 명세서는 암모니움 카바메이트를 질소 소스로 사용하여 엔아민을 중간체 화합물로 제조하고, 이를 다시 다른 화합물과 반응시켜 치환된 피리딘을 제조하는 방법에 관한 것이다. 본 명세서의 방법에 따르면 적어도 2단계로 이루어진 방법에 의하여 높은 수율과 짧은 반응 시간에 치환된 피리딘을 제조할 수 있다. 또한 이러한 방법에 따르면 무용매 및 무촉매 조건 하에서 반응을 진행하는 것이므로 배치 효율이 매우 높은 효과를 나타낸다. 그러므로, 의약 또는 약학 분야에 있어서, 치환된 피리딘을 제조하는 분야에서 널리 사용될 수 있다.
摘要:
The present invention relates to a novel organic electroluminescent compound and an organic electroluminescent device comprising the same. By using the organic electroluminescent compound according to the present invention, it is possible to produce an organic electroluminescent device having excellent current efficiency and lifespan characteristics.
摘要:
Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor- 1 alpha (HIF- lα), as well as hypoxia inducible factor-2 (HIF-2). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed compounds. Yet further disclosed are methods for stimulating the cellular immune response in a mammal such as increasing phagocytosis, for example, prolonging the life of phagocytes, inter alia , kerotyiocytes, neutrophils. As such the disclosed compounds provide methods for treating diseases that relate to the body's immune response.